tbuckley/cabot-search huggingface dataset:
A commentary on ‘Meta-analysis of clinical outcomes of robot-assisted partial nephrectomy and classical open partial nephrectomy’
Authors: Xinru Li, Xiaoang Ye, Hongyu Chen
Journal: International Journal of Surgery (2024)

aHangzhou Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China bThe Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China cDepartment of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang,People's Republic of China Xinru Li and Xiaoang Ye contributed equally to this work and share first authorship. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, 453 Stadium Road, West Lake District, Hangzhou, Zhejiang 310007, People's Republic of China. Tel.: +86 18057129786. E-mail address: [email protected] (H. Chen). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
Tat-dependent Conditionally Replicating Adenoviruses Expressing Diphtheria Toxin A for Specifically Killing HIV-1 Infected Cells
Authors: Fengfeng Ni, Kai Hu, Miaomiao Li, Mengshi Yang, Yingying Xiao, Ming Fu, Zhiyuan Zhu, Yalan Liu, Qinxue Hu
Journal: Molecular Therapy (2024)
Advancing generative AI in medicine: recommendations for standardized evaluation
Authors: Anqi Lin, Lingxuan Zhu, Weiming Mou, Zizhi Yuan, Quan Cheng, Aimin Jiang, Peng Luo
Journal: International Journal of Surgery (2024)

Lin, Anqi; Zhu, Lingxuan; Mou, Weiming; Yuan, Zizhi; Cheng, Quan; Jiang, Aimin; Luo, Peng Author Information
Development and field evaluation in African and Asian countries of an HBV PCR on open polyvalent platforms to determine treatment eligibility: results from the ANRS 12327 study
Authors: Dramane Kania, Janin Nouhin, Karine Bolloré, Richard Njouom, Thomas d'Aquin Toni, Almoustapha Issiaka Maiga, Coumba Toure-Kane, Nicole Ngo-Giang-Huong, Anoumou Dagnra, Duy Hoang Chuong Le, Françoise Lunel-Fabiani, Joany Castera-Guy, Pierre-Alain Rubbo, Amandine Pisoni, Jean-Christophe Plantier, Edouard Tuaillon
Journal: Clinical Microbiology and Infection (2024)
Beyond pulmonary rehabilitation: can the PICk UP programme fill the gap? A randomised trial in COPD
Authors: P. Rebelo, D. Brooks, J. Cravo, M.A. Mendes, A.C. Oliveira, A.S. Rijo, M.J. Moura, A. Marques
Journal: Pulmonology (2024)

Pulmonary rehabilitation (PR) is a fundamental intervention to manage COPD, however, maintaining its benefits is challenging. Engaging in physical activity might help to prolong PR benefits. This study assessed the efficacy and effectiveness of a personalised community-based physical activity programme to sustain physical activity and other health-related PR benefits, in people with COPD. This was a multicentre, assessor blinded, randomised controlled trial. Following 12-weeks of PR, people with COPD were assigned to a six-months personalised community-based physical activity programme (experimental group), or to standard care (control group). Physical activity was assessed via: time spent in moderate to vigorous physical activities per day (primary outcome measure), steps/day and the brief physical activity assessment tool. Secondary outcomes included sedentary behaviour, functional status, peripheral muscle strength, balance, symptoms, emotional state, health-related quality of life, exacerbations and healthcare utilization. Assessments were performed immediately post-PR and after three- and six-months. Efficacy and effectiveness were evaluated using intention-to-treat and per-protocol analysis with linear mixed models. Sixty-one participants (experimental group: n = 32; control group: n = 29), with balanced baseline characteristics between groups (69.6 ± 8.5 years old, 84 % male, FEV1 57.1 ± 16.7 %predicted) were included. Changes in all physical activity outcomes and in one-minute sit-to-stand were significantly different (P < 0.05) between groups at the six-month follow-up. In the remaining outcomes there were no differences between groups. The community-based physical activity programme resulted in better physical activity levels and sit-to-stand performance, six-months after completing PR, in COPD. No additional benefits were observed for other secondary outcomes.
Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials
Authors: Brendon L. Neuen, Brian L. Claggett, Vlado Perkovic, Meg Jardine, Hiddo J.L. Heerspink, Kenneth W. Mahaffey, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Journal: Circulation (2024)
A 3D In-vitro model of the human dentine interface shows long-range osteoinduction from the dentine surface
Authors: William Macalester, Asme Boussahel, Rafael O. Moreno-Tortolero, Mark R. Shannon, Nicola West, Darryl Hill, Adam Perriman
Journal: International Journal of Oral Science (2024)

Abstract Emerging regenerative cell therapies for alveolar bone loss have begun to explore the use of cell laden hydrogels for minimally invasive surgery to treat small and spatially complex maxilla-oral defects. However, the oral cavity presents a unique and challenging environment for in vivo bone tissue engineering, exhibiting both hard and soft periodontal tissue as well as acting as key biocenosis for many distinct microbial communities that interact with both the external environment and internal body systems, which will impact on cell fate and subsequent treatment efficacy. Herein, we design and bioprint a facile 3D in vitro model of a human dentine interface to probe the effect of the dentine surface on human mesenchymal stem cells (hMSCs) encapsulated in a microporous hydrogel bioink. We demonstrate that the dentine substrate induces osteogenic differentiation of encapsulated hMSCs, and that both dentine and β-tricalcium phosphate substrates stimulate extracellular matrix production and maturation at the gel-media interface, which is distal to the gel-substrate interface. Our findings demonstrate the potential for long-range effects on stem cells by mineralized surfaces during bone tissue engineering and provide a framework for the rapid development of 3D dentine-bone interface models.
Sinensetin protects against periodontitis through binding to Bach1 enhancing its ubiquitination degradation and improving oxidative stress
Authors: Zhiyao Yuan, Junjie Li, Fuyu Xiao, Yu Wu, Zhiting Zhang, Jiahong Shi, Jun Qian, Xudong Wu, Fuhua Yan
Journal: International Journal of Oral Science (2024)

Abstract Periodontitis is a chronic inflammatory and immune reactive disease induced by the subgingival biofilm. The therapeutic effect for susceptible patients is often unsatisfactory due to excessive inflammatory response and oxidative stress. Sinensetin (Sin) is a nature polymethoxylated flavonoid with anti-inflammatory and antioxidant activities. Our study aimed to explore the beneficial effect of Sin on periodontitis and the specific molecular mechanisms. We found that Sin attenuated oxidative stress and inflammatory levels of periodontal ligament cells (PDLCs) under inflammatory conditions. Administered Sin to rats with ligation-induced periodontitis models exhibited a protective effect against periodontitis in vivo. By molecular docking, we identified Bach1 as a strong binding target of Sin, and this binding was further verified by cellular thermal displacement assay and immunofluorescence assays. Chromatin immunoprecipitation-quantitative polymerase chain reaction results also revealed that Sin obstructed the binding of Bach1 to the HMOX1 promoter, subsequently upregulating the expression of the key antioxidant factor HO-1. Further functional experiments with Bach1 knocked down and overexpressed verified Bach1 as a key target for Sin to exert its antioxidant effects. Additionally, we demonstrated that Sin prompted the reduction of Bach1 by potentiating the ubiquitination degradation of Bach1, thereby inducing HO-1 expression and inhibiting oxidative stress. Overall, Sin could be a promising drug candidate for the treatment of periodontitis by targeting binding to Bach1.
Proteomics and metabolomics of sputum reveal the potential impact of allergic rhinitis on asthma
Authors: Yujuan Yang, Limei Cui, Pengyi Yu, Jing Guo, Jianwei Wang, Hanrui Wang, Zheying Song, Zhaoxue Zhai, Tong Li, Guangkuo Wang, Yuemei Sun, Yu Zhang, Xicheng Song
Journal: Allergy (2024)

The raw data of this study are available from the corresponding author. Data S1: Figure S1. Figure S2. Figure S3. Figure S4. Figure S5. Table S3. Table S4. Table S5. Table S6. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The <scp>FINEARTS‐HF</scp> trial
Authors: Scott D Solomon, John W Ostrominski, Muthiah Vaduganathan, Brian Claggett, Pardeep S Jhund, Akshay S Desai, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Imran Zainal Abidin, Marco Antonio Alcocer-Gamba, John J Atherton, Johann Bauersachs, Chang‐sheng Ma, Chern‐en Chiang, Ovidiu Chioncel, Vijay Chopra, Josep Comin-Colet, Gerasimos Filippatos, Cândida Fonseca, Grzegorz Gajos, Sorel Goland, Eva Goncalvesová, Seok‐min Kang, Tzvetana Katova, Mikhail N Kosiborod, Gustavs Latkovskis, Alex Pui‐wai Lee, Gerard C.M. Linssen, Guillermo Llamas-Esperón, Vyacheslav Mareev, Felipe A Martinez, Vojtěch Melenovský, Béla Merkely, Savina Nodari, Mark C Petrie, Clara Inés Saldarriaga, Jose Francisco Kerr Saraiva, Naoki Sato, Morten Schou, Kavita Sharma, Richard Troughton, Jacob A Udell, Heikki Ukkonen, Orly Vardeny, Subodh Verma, Dirk von Lewinski, Leonid G Voronkov, Mehmet Birhan Yilmaz, Shelley Zieroth, James Lay-Flurrie, Ilse van Gameren, Flaviana Amarante, Prabhakar Viswanathan, John J.V. McMurray
Journal: European Journal of Heart Failure (2024)

Aims To describe the baseline characteristics of participants in the FINEARTS‐HF trial, contextualized with prior trials including patients with heart failure (HF) with mildly reduced and preserved ejection fraction (HFmrEF/HFpEF). The FINEARTS‐HF trial is comparing the effects of the non‐steroidal mineralocorticoid receptor antagonist finerenone with placebo in reducing cardiovascular death and total worsening HF events in patients with HFmrEF/HFpEF. Methods and results Patients with symptomatic HF, left ventricular ejection fraction (LVEF) ≥40%, estimated glomerular filtration rate ≥ 25 ml/min/1.73 m 2 , elevated natriuretic peptide levels and evidence of structural heart disease were enrolled and randomized to finerenone titrated to a maximum of 40 mg once daily or matching placebo. We validly randomized 6001 patients to finerenone or placebo (mean age 72 ± 10 years, 46% women). The majority were New York Heart Association functional class II (69%). The baseline mean LVEF was 53 ± 8% (range 34–84%); 36% of participants had a LVEF &lt;50% and 64% had a LVEF ≥50%. The median N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) was 1041 (interquartile range 449–1946) pg/ml. A total of 1219 (20%) patients were enrolled during or within 7 days of a worsening HF event, and 3247 (54%) patients were enrolled within 3 months of a worsening HF event. Compared with prior large‐scale HFmrEF/HFpEF trials, FINEARTS‐HF participants were more likely to have recent (within 6 months) HF hospitalization and greater symptoms and functional limitations. Further, concomitant medications included a larger percentage of sodium–glucose cotransporter 2 inhibitors and angiotensin receptor–neprilysin inhibitors than previous trials. Conclusions FINEARTS‐HF has enrolled a broad range of high‐risk patients with HFmrEF and HFpEF. The trial will determine the safety and efficacy of finerenone in this population.
Correction to “Overcome the “Buckets Effect”: Integration of AIEgens into Proteins for Fluorescence‐Enhanced Two‐Photon Imaging”
Authors: Miaozhuang Fan, Zhengzheng Li, Gang Feng, Yibing Zhang, Wenguang Zhang, Chengbin Yang, Yonghong Shao, Changrui Liao, Gaixia Xu, Zhourui Xu
Journal: Advanced Healthcare Materials (2024)

Overcome the "Buckets Effect": Integration of AIEgens into Proteins for Fluorescence-Enhanced Two-Photon Imaging. Adv. Healthcare Mater. 2023, 12, 2301568, https://doi.org/10.1002/adhm.202301568 In the section 2.5 "Toxicity Assessment of MTAA@BSA" of the article, the histological analysis result in Figure 5 was misused. The correct version of Figure 5 is shown below. We apologize for this error. The correct version of Figure 5.
Reply to Ping Zhong, Xin Liu, and Limin Liao’s Letter to the Editor re: Michele Gnech, Lisette ’t Hoen, Alexandra Zachou, et al. Update and Summary of the European Association of Urology/European Society of Paediatric Urology Paediatric Guidelines on Vesicoureteral Reflux in Children. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.12.005
Authors: Michele Gnech, Lisette 't Hoen, Berk Burgu, Christian Radmayr
Journal: European Urology (2024)
Sacubitril/valsartan and cardiovascular biomarkers among patients with recent <scp>COVID</scp>‐19 infection: The <scp>PARACOR</scp>‐19 randomized clinical trial
Authors: Stephen J. Greene, RaKavius Chambers, Joseph B. Lerman, Josephine Harrington, Christopher R deFilippi, David C. Wendell, Han W. Kim, Cynthia L. Green, Javed Butler, G. Michael Felker
Journal: European Journal of Heart Failure (2024)
Cost‐effectiveness of sutimlimab in cold agglutinin disease
Authors: Satoko Ito, Daniel Wang, Adriana Purcell, Karthik Chetlapalli, Alfred I. Lee, Adam Cuker, George Goshua
Journal: American Journal of Hematology (2024)

Abstract Primary cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by cold‐reactive antibodies that bind to red blood cells and lead to complement‐mediated hemolysis. Patients with primary CAD experience the burden of increased health resource utilization and reduced quality of life. The standard‐of‐care (SOC) in patients with primary CAD has included cold avoidance, transfusion support, and chemoimmunotherapy. The use of sutimlimab, a humanized monoclonal antibody that selectively inhibits C1‐mediated hemolysis, was shown to reduce transfusion‐dependence and improve quality of life across two pivotal phase 3 studies, further supported by 2‐year extension data. Using data from the transfusion‐dependent patient population that led to sutimlimab's initial FDA approval, we performed the first‐ever cost‐effectiveness analysis in primary CAD. The projected incremental cost‐effectiveness ratio (ICER) in our Markov model was $2 340 000/QALY, significantly above an upper‐end conventional US willingness‐to‐pay threshold of $150 000/QALY. These results are consistent across scenarios of higher body weight and a pan‐refractory SOC patient phenotype (i.e., treated sequentially with bendamustine‐rituximab, bortezomib, ibrutinib, and eculizumab). No parameter variations in deterministic sensitivity analyses changed our conclusion. In probabilistic sensitivity analysis, SOC was favored over sutimlimab in 100% of 10 000 iterations. Exploratory threshold analyses showed that significant price reduction (&gt;80%) or time‐limited treatment (&lt;18 months) followed by lifelong clinical remission off sutimlimab would allow sutimlimab to become cost‐effective. The impact of sutimlimab on health system costs with longer term follow‐up data merits future study and consideration through a distributional cost‐effectiveness framework.
Context-dependent role of trisomy 6 in myelodysplastic neoplasms and acute myeloid leukemia: a multi-omics analysis
Authors: Hussein Awada, Arda Durmaz, Tariq Kewan, Fauzia Ullah, Danai Dima, Hassan Awada, Simona Pagliuca, Manja Meggendorfer, Torsten Haferlach, Carmelo Gurnari, Valeria Visconte, Jaroslaw P Maciejewski
Journal: Leukemia (2024)
Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions
Authors: Nicholas J Short, Elias Jabbour, Nitin Jain, Hagop Kantarjian
Journal: Journal of Hematology & Oncology (2024)

Abstract Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be highly effective in acute lymphoblastic leukemia (ALL). INO improved response rates and survival in a randomized study in adults with relapsed/refractory B-cell ALL, leading to its regulatory approval in the United States in 2017. While the formal approval for INO is as monotherapy in relapsed/refractory ALL, subsequent studies with INO administered in combination with chemotherapy and/or blinatumomab both in the frontline and salvage settings have yielded promising results. In this review, we discuss the clinical development of INO in ALL, highlighting lessons learned from the initial clinical trials of INO, as well as the many ongoing studies that are seeking to expand the role of INO in ALL.
Diuresis Efficacy in Ambulatory Congested Heart Failure Patients
Authors: Aharon Ronnie Abbo, Amit Gruber, Ina Volis, Doron Aronson, Nicolas Girerd, Søren Lund Kristensen, Robert Zukermann, Natalia Alberkant, Elena Sitnitsky, Anton Kruger, Polina Khasis, Evgeny Bravo, Boaz Elad, Ludmila Helmer Levin, Oren Caspi
Journal: JACC Heart Failure (2024)
Locationally activated PRP via an injectable dual-network hydrogel for endometrial regeneration
Authors: Jia Qi, Xiaoxiao Li, Yumeng Cao, Yijing Long, Junliang Lai, Yejie Yao, Yiwen Meng, Yuan Wang, Xiao-Dong Chen, Hugo Vankelecom, Xuejiao Bian, Wenguo Cui, Yun Sun
Journal: Biomaterials (2024)
Ionizable lipid nanoparticles for RAS protease delivery to inhibit cancer cell proliferation
Authors: Ella Atsavapranee, Rebecca M. Haley, Margaret M. Billingsley, Alexander Chan, Biao Ruan, Christian G. Figueroa-Espada, Ningqiang Gong, Alvin J. Mukalel, Philip N. Bryan, Michael J. Mitchell
Journal: Journal of Controlled Release (2024)
Biomimetic hydrogels with mesoscale collagen architecture for patient-derived tumor organoids culture
Authors: Jiaxin Wang, Zhilin Sui, Wei Huang, Zhentao Yu, Ling Guo
Journal: Bioactive Materials (2024)

Patient-derived tumor organoids (PDTOs) shows great potential as a preclinical model. However, the current methods for establishing PDTOs primarily focus on modulating local properties, such as sub-micrometer topographies. Nevertheless, they neglect to capture the global millimeter or intermediate mesoscale architecture that have been demonstrated to influence tumor response to therapeutic treatment and tumor progression. In this study, we present a rapid technique for generating collagen bundles with an average length of 90 ± 27 μm and a mean diameter of 5 ± 1.5 μm from tumor tissue debris that underwent mechanical agitation following enzymatic digestion. The collagen bundles were subsequently utilized for the fabrication of biomimetic hydrogels, incorporating microbial transglutaminase (mTG) crosslinked gelatin. These biomimetic hydrogels, referred to as MC-gel, were specifically designed for patient-derived tumor organoids. The lung cancer organoids cultured in MC-gel exhibited larger diameters and higher cell viability compared to those cultured in gels lacking the mesoscale collagen bundle; moreover, their irregular morphology more closely resembled that observed
A novel microporous biomaterial vaccine platform for long-lasting antibody mediated immunity against viral infection
Authors: Daniel P. Mayer, Mariah E. Nelson, Daria Andriyanova, Renata B. Filler, Arya Ökten, Olivia Q. Antao, Jennifer S. Chen, Philip O. Scumpia, Westbrook M. Weaver, Craig B. Wilen, Stephanie Deshayes, Jason S. Weinstein
Journal: Journal of Controlled Release (2024)

Current antigen delivery platforms, such as alum and nanoparticles, are not readily tunable, thus may not generate optimal adaptive immune responses. We created an antigen delivery platform by loading lyophilized Microporous Annealed Particle (MAP) with aqueous solution containing target antigens. Upon administration of antigen loaded MAP (VaxMAP), the biomaterial reconstitution forms an instant antigen-loaded porous scaffold area with a sustained release profile to maximize humoral immunity. VaxMAP induced CD4
Addressing Health Disparities—The Case for Variant Transthyretin Cardiac Amyloidosis Grows Stronger
Authors: Mathew S. Maurer, Edward J. Miller, Frederick L. Ruberg
Journal: JAMA (2024)

Senthil Selvaraj, MD, MS, MA; Brian Claggett, PhD; Svati H. Shah, MD, MHS; Robert J. Mentz, MD; Michel G. Khouri, MD; Ani W. Manichaikul, PhD; Sadiya S. Khan, MD, MSc; Stephen S. Rich, PhD; Thomas H. Mosley, PhD; Emily B. Levitan, ScD; Pankaj Arora, MD; Parag Goyal, MD, MSc; Bernhard Haring, MD, MPH; Charles B. Eaton, MD, MS; Richard K. Cheng, MD, MSc; Gretchen L. Wells, MD, PhD; JoAnn E. Manson, MD, MPH, DrPH; Marianna Fontana, MD, PhD; Scott D. Solomon, MD
Cardiovascular Burden of the V142I Transthyretin Variant
Authors: Senthil Selvaraj, Brian Claggett, Svati H. Shah, Robert J. Mentz, Michel G. Khouri, Ani W. Manichaikul, Sadiya S. Khan, Stephen S. Rich, Thomas H. Mosley, Emily B. Levitan, Pankaj Arora, Parag Goyal, Bernhard Haring, Charles B. Eaton, Richard K. Cheng, Gretchen L. Wells, JoAnn E. Manson, Marianna Fontana, Scott D. Solomon
Journal: JAMA (2024)

Individual cohort studies concur that the amyloidogenic V142I variant of the transthyretin (TTR) gene, present in 3% to 4% of US Black individuals, increases heart failure (HF) and mortality risk. Precisely defining carrier risk across relevant clinical outcomes and estimating population burden of disease are important given established and emerging targeted treatments.
Heart Failure in African American Individuals, Version 2.0
Authors: Clyde W. Yancy
Journal: JAMA (2024)

Senthil Selvaraj, MD, MS, MA; Brian Claggett, PhD; Svati H. Shah, MD, MHS; Robert J. Mentz, MD; Michel G. Khouri, MD; Ani W. Manichaikul, PhD; Sadiya S. Khan, MD, MSc; Stephen S. Rich, PhD; Thomas H. Mosley, PhD; Emily B. Levitan, ScD; Pankaj Arora, MD; Parag Goyal, MD, MSc; Bernhard Haring, MD, MPH; Charles B. Eaton, MD, MS; Richard K. Cheng, MD, MSc; Gretchen L. Wells, MD, PhD; JoAnn E. Manson, MD, MPH, DrPH; Marianna Fontana, MD, PhD; Scott D. Solomon, MD
Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Impaired Renal Function
Authors: Shingo Matsumoto, Alasdair D. Henderson, Li Shen, Mingming Yang, Karl Swedberg, Muthiah Vaduganathan, Dirk J. van Veldhuisen, Scott D. Solomon, Bertram Pitt, Faiez Zannad, Pardeep S. Jhund, John J.V. McMurray
Journal: Journal of the American College of Cardiology (2024)